免疫检查点抑制剂治疗驱动基因阳性晚期非小细胞肺癌的研究进展  

Research progress in immune checkpoint inhibitors in the treatment of oncogene-driven advanced non-small cell lung cancer

作　　者：李语馨 张乐蒙 陈建华 LI Yuxin;ZHANG Lemeng;CHEN Jianhua(First Department of Thoracic Medicine,Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China)

机构地区：[1]中南大学湘雅医学院附属肿瘤医院胸内一科,长沙410013

出　　处：《中南大学学报（医学版）》2020年第4期418-425,共8页Journal of Central South University ：Medical Science

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)已成为晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的重要治疗方法,但其在驱动基因阳性患者中的疗效仍存在争议。现有研究显示:ICIs的疗效可能与不同的驱动基因类型、程序性死亡蛋白-配体1(programmed cell death-ligand 1,PD-L1)表达水平、肿瘤突变负荷(tumor mutational burden,TMB)等相关,同时可能需要参考其他因素,如临床特征、免疫细胞密度等。ICIs单药或联合治疗可能会在一部分驱动基因阳性NSCLC患者中发挥作用,但仍需要进一步研究来筛选出这些患者,这或许是晚期NSCLC治疗未来发展的一个重要方向。The clinical application of immune checkpoint inhibitors(ICIs)lead to dramatic changes in the treatment strategy for patients with advanced non-small cell lung cancer(NSCLC),but the efficacy of ICIs in oncogene-driven NSCLC is controversial.Existing research shows that the efficacy of ICIs may be related to different types of driver genes,programmed cell death-ligand 1(PD-L1)level,and tumor mutational burden(TMB).It may involved in other factors,such as clinical characteristics,and immune cell density.ICIs monotherapy or combination therapy may play a role in a subset of oncogene-driven NSCLC patients,but further studies are needed to select these patients,which may be an important direction for the future development of advanced NSCLC.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 驱动基因 表皮生长因子受体 间变性淋巴瘤激酶 V-Ki-Ras2 Kirsten大鼠肉瘤病毒癌基因同源物 BRAF 程序性死亡蛋白-配体1 

分 类 号：R734.2[医药卫生—肿瘤]